VE1 immunohistochemistry as a screening tool for BRAFV600E mutation in lung adenocarcinoma: evidence from a Montenegro National Cohort

Immunohistochemistry using VE1 antibody is a reliable and accessible initial screening tool for BRAFV600E mutation in lung adenocarcinoma. Strong, homogeneous cytoplasmic staining predicts mutation status with high accuracy, while weak or heterogeneous staining requires confirmatory molecular testing. The present findings provide essential local epidemiological data and support universal IHC testing to guide personalized therapy in NSCLC.